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abstract
Background: Cardiovascular disease (CVD) has been the 
leading cause of death in developed countries for most of the 
last century. Most CVD deaths, however, occur in low- and 
middle-income, developing countries (LMICs) and there is 
great concern that CVD mortality and burden are rapidly 
increasing in LMICs as a result of population growth, ageing 
and health transitions. In sub-Saharan Africa (SSA), where 
all countries are part of the LMICs, the pattern, magnitude 
and trends in CVD deaths remain incompletely understood, 
which limits formulation of data-driven regional and national 
health policies. 
Objective: The aim was to estimate the number of deaths, 
death rates, and their trends for CVD causes of death in SSA, 
by age and gender for 1990 and 2013. 
Methods: Age- and gender-specific mortality rates for CVD 
were estimated using the Global Burden of Disease (GBD) 
2010 methods with some refinements made by the GBD 2013 
study to improve accuracy. Cause of death was estimated as 
in the GBD 2010 study and updated with a verbal autopsy 
literature review and cause of death ensemble modelling 
(CODEm) estimation for causes with sufficient information. 
For all quantities reported, 95% uncertainty intervals (UIs) 
were also computed.
Results: In 2013, CVD caused nearly one million deaths in 
SSA, constituting 38.3% of non-communicable disease deaths 
and 11.3% of deaths from all causes in that region. SSA 
contributed 5.5% of global CVD deaths. There were more 
deaths in women (512 269) than in men (445 445) and more 
deaths from stroke (409 840) than ischaemic heart disease 
(258 939). Compared to 1990, the number of CVD deaths in 
SSA increased 81% in 2013. Deaths for all component CVDs 
also increased, ranging from a 7% increase in incidence of 
rheumatic heart disease to a 196% increase in atrial fibril-
lation. The age-standardised mortality rate (per 100 000) in 
1990 was 327.6 (CI: 306.2–351.7) and 330.2 (CI: 312.9–360.0) 
in 2013, representing only a 1% increase in more than two 
decades. 
Conclusions: In SSA, CVDs are neither epidemic nor among 
the leading causes of death. However, a significant increase 
in the number of deaths from CVDs has occurred since 1990, 
largely as a result of population growth, ageing and epide-
miological transition. Contrary to what has been observed 
in other world regions, the age-adjusted mortality rate for 
CVD has not declined. Another important difference in CVD 
deaths in SSA is the predominance of stroke as the leading 
cause of death. Attention to aggressive efforts in cardiovas-
cular health promotion and CVD prevention, treatment and 
control in both men and women are warranted. Additionally, 
investments to improve directly enumerated epidemiological 
data for refining the quantitation of risk exposures, death 
certification and burden of disease assessment will be crucial.
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Cardiovascular disease (CVD), principally ischaemic heart 
disease and stroke, constitute the leading cause of global 
mortality, and accounted for 17.3 million deaths worldwide in 
2013.1 In high-income, developed countries, CVDs have been the 
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leading cause of death throughout most of the last century. In 
the United States, for example, heart disease has been the leading 
cause of death every year since 1918.2 Currently, however, 
most CVD deaths occur in low- and middle-income countries 
(LMIC) and there is growing concern that an epidemic of CVDs 
is emerging in these countries that must be prevented.3,4 The 
World Health Organisation (WHO) and the United Nations 
have also called attention to a rising burden of CVD and other 
non-communicable diseases and the need for aggressive measures 
to forestall this epidemic in these countries5,6 
In sub-Saharan Africa (SSA), where all countries are part 
of the developing world, the magnitude of and trends in CVD 
deaths remain incompletely understood. The African regional 
office of the WHO has stated that CVDs are ‘increasing rapidly 
in Africa, and it is now a public health problem throughout the 
African region’.7 However, a systematic analysis of estimates for 
CVD mortality in the Global Burden of Disease (GBD) 2010 
study showed no significant rise in age-standardised mortality 
rates for CVD in SSA for the period of 1990–2010.8,9 Similarly, 
recent data from the INDEPTH Health and Demographic 
Surveillance System show little evidence of NCD mortality rates 
increasing over time.10,11 However, data on CVDs are limited in 
the region,12-14 and novel methods are required in order to make 
meaningful estimates. 
Clarifying the epidemiology of CVD in SSA is essential 
for the formulation of regional and national health policies. 
Accordingly, we explored as a primary objective, estimates of the 
number of deaths, age-standardised and age- and gender-specific 
mortality rates, and their trends in SSA, by age and gender, for 
the period 1990–2013 for total CVD, rheumatic heart disease 
(RHD), ischaemic heart disease (IHD), cerebrovascular disease 
(including ischaemic and haemorrhagic stroke), hypertensive 
heart disease, cardiomyopathy and myocarditis, atrial fibrillation 
and flutter, aortic aneurysm, peripheral arterial disease (PAD) 
and endocarditis. These data for SSA were also compared to data 
for developing and developed countries.
Methods
Age and gender year-specific mortality rates for CVD were 
estimated using the methods as published in the GBD 2013 
study.1 In brief, the GBD 2013 study collected all available data 
on mortality, including vital registration and verbal autopsy. 
Raw data were corrected to account for outliers and non-specific 
causes of death (i.e. ‘garbage’ codes). 
Modelling was performed using a custom ensemble-model 
approach (CODem) to estimate deaths for each country, 
including countries without data.15 CODem employs Gaussian 
process regression and spatio-temporal modelling, as well as 
cardiovascular-specific covariates, such as systolic blood pressure, 
to produce consistent estimates.1 Estimates were adjusted to 
fit an envelope of all-cause mortality and all-cardiovascular 
mortality to ensure that no strata contained more deaths that 
occurred for any of its parent categories. 
For SSA, mortality data for the years 1980–2011 were 
used from Madagascar, Ethiopia, Mauritius, Seychelles, South 
Africa, Zambia, Mozambique, Kenya, Tanzania, Burkino Faso, 
Zimbabwe, Mali and Ghana. For all quantities reported, 95% 
uncertainty intervals (UIs) were also computed using 1 000 
draws from the posterior distribution of each age–gender–
country–year-specific set of estimates. Death numbers from each 
country and each cause were summed to produce estimates for 
the entire region of SSA.
results 
As shown in Table 1, CVDs caused nearly one million deaths 
in SSA in 2013. The number of deaths in women (512 269) 
exceeded those in men (445 445) for total CVDs and also for all 
cardiovascular causes of death except ischaemic heart disease, 
aortic aneurysms and peripheral vascular disease. There were 
more deaths from stroke (409 840) than ischaemic heart disease 
(258 939). Compared to 1990, CVD deaths increased 81% in 
2013. Similarly, deaths for all component CVDs also increased, 
ranging from a 7% increase in rheumatic heart disease to a 196% 
increase in atrial fibrillation. The age-standardised mortality rate 
(per 100 000) for total CVD in 1990 was 327.6 (CI: 306.2–351.7) 
and 330.2 (CI: 312.9–360.0) in 2013, representing a 1% increase. 
As previously demonstrated, SSA experiences the world’s 
lowest IHD death rates, and IHD ranks below stroke as a leading 
cause of CVD death in the region.12 On average, SSA experienced 
no significant change in age-standardised IHD mortality rate 
table 1. total number of deaths and age-standardised mortality rates for component cardiovascular causes of death  
in 1990 and 2013 and the respective percentage changes
Cause
Number 
of 
deaths, 
1990 95% UI
Number 
of 
deaths, 
2013 95% Ul
% 
Change
Age-standard-
ized death rate 
(per 100 000), 
1990 95% UI
Age-standard-
ized death rate 
(per 100 000), 
1990 95%UI
% 
Change
Ischaemic heart disease 138 308 (116 618 – 153 645) 258 939 (232 158 – 305 680) 87 91.4 (76.9 – 101.7) 92.9 (82.8 – 110.2) 2
Ischaemic stroke 101 040 (77 903 – 117 660) 206 439 (139 860 – 242 225) 104 75.0 (57.2 – 87.5) 81.5 (55.0 – 95.7) 9
Hemorrhagic stroke 125 603 (103 055 – 147 517) 203 401 (173 620 – 262 418) 62 72.2 (57.1 – 87.6) 64.7 (54.0 – 87.5) –10
Hypertensive heart disease 37 525 (29 485 – 49 443) 86 035 (62 970 – 111 978) 129 26.8 (21.0 – 36.5) 32.8 (24.2 – 44.0) 22
Cardiomyopathy 28 917 (23 557 – 36 082) 53 742 (44 926 – 65 634) 86 12.7 (10.6 – 17.0) 14.5 (11.9 – 18.2) 14
Rheumatic heart disease 23 625 (17 644 – 31 608) 25 239 (20 478 – 40 444) 7 10.3 (7.5 – 13.7) 6.5 (5.3 – 10.1) –37
Atrial fibrillation 414 (331 – 509) 1 227 (959 – 1 558) 196 0.4 (0.3 – 0.5) 0.6 (0.5 – 0.8) 50
Aortic aneurysm 5 150 (3 370 – 6 714) 9 854 (7 809 – 12 840) 91 3.3 (2.2 – 4.3) 3.4 (2.7 – 4.5) 3
Peripheral vascular disease 469 (371 – 580) 1 338 (1 122 – 1 618) 185 0.4 (0.3 – 0.5) 0.6 (0.5 – 0.7) 50
Endocarditis 9 622 (6 339 – 15 825) 13 868 (10 967 – 18 524) 44 4.7 (3.0 – 8.6) 3.7 (2.9 – 5.3) –21
Other cardiovascular diseases 59 206 (48 291 – 74 859) 98 632 (77 904 – 138 971) 67 30.3 (24.8 – 41.1) 29.1 (22.7 – 42.8) –4
Total cardiovascular diseases 529 880 (492 351 – 568 410) 958 713 (909 427 – 1 049 606) 81 327.6 (306.2 – 351.7) 330.2 (312.9 – 360.0) 1
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between 1990 and 2013, however, likely due to aging and growth 
of the SSA population, the number of IHD deaths increased by 
87% over the same interval (Table 1). 
As shown in Fig. 1 for both men and women, the number 
of CVD deaths in SSA was substantially lower than that seen 
for either the developed or developing countries.   Contrary to 
the pattern seen for developed and developing countries (as a 
whole), the age-standardised mortality rate for CVD in both men 
and women in SSA did not decline during the period from 1990 
to 2013 (Fig. 1).  In fact, the age-standardised mortality rate for 
women in SSA, which was lower than the corresponding rate in 
women in developing countries in 1990, is now higher than the 
rate seen for women in developing countries, and substantially 
higher than the corresponding rates for both men and women in 
the developed world (Fig. 1).
The number of deaths from stroke in SSA nearly doubled 
from 1990 to 2013, but overall age-adjusted stroke mortality 
rates decreased by 1% (increased by 9% for ischaemic stroke 
and decreased by 10% for haemorrhagic stroke). The increase 
in number of stroke deaths in SSA was particularly noticeable 
for ischaemic stroke (104% increases in 2013 compared to 1990), 
although age-adjusted stroke mortality rates in SSA regions were 
one of the lowest in LMIC and only slightly higher than that in 
developed countries, compared with GBD 2010 stroke mortality 
estimates. Although the majority of deaths from stroke in SSA 
in 1990 were due to haemorrhagic strokes (55%), in 2013 the 
proportional frequency of deaths from haemorrhagic stroke 
was slightly lower (49.6%) than that from ischaemic stroke. 
Compared to GBD 2010 stroke mortality estimates, the mean 
age at death from stroke in SSA was the lowest among all LMIC. 
In 1990 the total number of deaths from PAD was 469 
(CI: 371–580) compared with 1 338 (CI: 1 122–1 618) in 2013, 
representing a 185% increase. There were 277 (CI: 204–366) 
deaths due to PAD among men, which was higher than the 192 
(CI: 145–271) deaths observed among women. Similarly, in 2013, 
the number of PAD deaths among men was 728 (CI: 578–902), 
which was also higher than the 610 (CI: 480–817) deaths 
observed among women. The combined age-standardised death 
rates per 100 000 were 0.4 (CI: 0.3–0.5) and 0.6 (CI: 0.5–0.7) in 
1990 and 2013, respectively, representing a 50% increase during 
the 23-year period. The age-standardised death rates for men 
were 0.5 (CI: 0.3–0.6) in 1990 and 0.6 (CI: 0.5–0.8) in 2013, which 
represents a 20% increase. However, women had a 66% increase 
in age-standardised death rates, as evidenced by the change from 
0.3 (CI: 0.2–0.5) in 1990 to 0.5 (CI: 0.4–0.7) in 2013.
The total number of deaths from atrial fibrillation was 414 
(331–509) in 1990, compared with 1 227 (CI: 959–1 558) in 2013, 
representing an increase of 196%. However, the age-standardised 
death rates (per 100 000) increased by 50% during the study 
period from 0.4 (CI: 0.3–0.5) in 1990 to 0.6 (CI: 0.5–0.8) in 
2013. In 1990 there were 148 (CI: 106–193) deaths due to 
atrial fibrillation among men, which was less than the 266 
(CI: 201–347) deaths observed among women. In 2013 there 
was a similar pattern of fewer AFIB deaths in men compared 
with women: 378 (CI: 295–490) vs 848 (CI: 605–1 170). The 
age-standardised death rates for men were 0.3 (CI: 0.2–0.4) in 
1990 and 0.4 (CI: 03–0.5) in 2013. The corresponding rates for 
women were 0.5 (CI: 0.3–0.7) and 0.7 (CI: 0.5–1.0), respectively.
The mortality rate from PAD in SSA has increased over the 
last 23 years. Furthermore, the relative increase in PAD mortality 
rate among women has been more dramatic than among men. 
Similar findings are noted for AFIB, wherein we actually 
observed a higher number of deaths and age-standardised death 
rates among women compared with men. 
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Fig. 1.  Number of CVD deaths in men (A) and women (B) in 1990 and 2013 in sub-Saharan Africa, developing countries, and in 
developed countries. Age-standardised CVD death rates per 100 000 population are shown for men (C) and women (D) in 
1990 and 2013 in sub-Saharan Africa, developing countries, and in developed countries.
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discussion
The most prominent finding in this study was that the 
age-standardised mortality rate for CVD has not declined in 
SSA, in sharp contrast to the dramatic declines that have been 
documented in other world regions, especially in the high-income, 
developed world. It is of concern that the age-standardised 
mortality rate for CVD in SSA women, which was lower than the 
corresponding rate in women in developing countries in 1990, 
is now higher than in developing countries, and substantially 
higher than corresponding rates in the developed world. In fact, 
a previous analysis of the GBD 2013 data on demographic and 
epidemiological drivers of global CVD mortality suggested that 
age-specific death rates for western sub-Saharan Africa may 
have increased.16 These findings have significant implications for 
effective prevention and treatment of CVD in SSA.
A second important observation from this study was that 
although most CVD deaths occur in developing countries, the 
overall number of CVD deaths in SSA is substantially lower 
than seen in the rest of the developed and developing world, 
and amounts to 5.5% of global CVD deaths. In addition, these 
CVD deaths in SSA constitute 38.3% of non-communicable 
disease deaths and 11.3% of deaths from all causes in that 
region.1 Therefore the assertion that CVD deaths represent an 
emerging epidemic may be unwarranted. Importantly, however, 
the approximately one million deaths in 2013 in SSA represent 
a near doubling of the deaths a decade earlier. Roth et al.16 have 
showed that population growth and ageing accounted for the 
increase in the number of global deaths due to CVD between 
1990 and 2013, despite an overall decrease in age-specific death 
rates for most regions.16 
A careful analysis of the data from SSA to determine the 
role that population growth, ageing and health transitions 
play in these deaths is needed. Uniformly however, component 
CVD deaths increased by a range from 7% for RHD to nearly 
a three-fold increase in atrial fibrillation and peripheral arterial 
disease. The good news from the data is the relative decline in the 
age-standardised mortality rates for RHD, haemorrhagic stroke 
and endocarditis.
This study has several limitations. Some cardiovascular causes 
of death are less commonly reported as an underlying cause 
of death. These diseases include rheumatic heart disease, atrial 
fibrillation, peripheral vascular disease, endocarditis and aortic 
aneurysms. Changes over time in the detection and reporting 
of these conditions most likely reflect not just epidemiological 
changes but changes in diagnostics and the ways that these 
diagnoses are attributed to deaths by physicians. Rheumatic 
heart disease-related mortality may be particularly difficult to 
attribute as a cause of death, which increases uncertainty for 
estimates of this condition.
Importantly, data sources on disease burden in SSA are among 
the most limited in the world, despite several comprehensive 
networks for data collection related to maternal and child 
mortality. Unfortunately a functioning vital records system can 
only be built in a society with a functioning primary health 
system that provides broad access – a concept that remains 
a serious challenge for most of SSA within the foreseeable 
future. Verbal autopsy and sample vital registration will likely 
expand as countries expand their investment in health system 
infrastructure.
Efforts should focus on improving comparability across 
countries and regions within SSA. Increased attention to 
non-communicable diseases will help highlight the important 
role of routine surveillance, rather than one-off research studies, 
as an important source of descriptive statistics related to CVD 
in SSA.
Conclusions
SSA has seen no significant decline in age-standardised CVD 
mortality rates, whereas these rates continue to fall dramatically 
in most of the high- and middle-income world. Without further 
investment in the prevention and treatment of CVD and other 
NCDs and their risk factors in SSA, the continent risks being left 
behind at a time when improved detection, prevention, treatment 
and control of these diseases and risk factors are leading to 
longevity and improved quality of life in other world regions. 
These decisions should be informed ideally by reliably accurate, 
directly enumerated data, rather than estimates such as those 
presented in this study.
The relative lack of directly enumerated epidemiological data, 
coupled with the absence of vital registration systems in 42 of 
the 46 SSA countries, presents major challenges in mortality 
and burden of disease data for this region. The estimates of 
mortality presented here must therefore be interpreted with 
caution. Nevertheless, we found no evidence to support a rapidly 
rising epidemic or an impending pandemic of CVD in SSA. 
However, the consistency of the directional changes in CVD 
deaths, disability and risk-factor trends observed in GBD 2010, 
and the mortality trends seen in GBD 2013, together with the 
young average age at time of death from CVDs in SSA, compel 
attention to aggressive efforts at CVD risk-factor prevention, 
treatment and control in both women and men. Coordinated 
partnerships between ministries of health, other government 
agencies, non-governmental organisations, and the private sector 
will be essential in order to mount a targeted response to the 
observed challenges.
Interventions at the individual and population levels as 
well as improved systems of healthcare will be required. In 
addition, investments to improve local-level directly enumerated 
epidemiological data and refinement of the quantitation of risk 
exposure, death certification and burden of disease assessment 
will be crucial. Further research is needed to identify ideal 
dissemination and implementation strategies for CVD risk 
reduction in the SSA setting. 
Until then, finding ways to implement interventions that 
are feasible, affordable and acceptable to the local population 
and are appropriate to implement in low-resource settings 
for the prevention and control of CVD in Africa should be a 
priority.17 This strategy is particularly relevant for the clinical and 
public health approaches for addressing hypertension, diabetes, 
unhealthy diet, physical inactivity and tobacco use. Improving 
access to directly enumerated epidemiological data for the 
region would also go a long way towards appropriately informed 
healthcare policy and practice.
The views expressed in this article are those of the authors and do not neces-
sarily represent the views of the National Heart, Lung, and Blood Institute, 
National Institutes of Health, or the US Department of Health and Human 
Services.
S10 AFRICACVJAFRICA • Volume 26, No 2, H3Africa Supplement, March/April 2015
References
1. GBD 2013 Mortality and Causes of Death Collaborators. Global, 
regional, and national age–sex specific all-cause and cause-specific 
mortality for 240 causes of death, 1990–2013: a systematic analysis for 
the Global Burden of Disease Study 2013. Lancet 2014; 14: 10–6736.
2. National Center for Health Statistics. National Vital Statistics System 
HIST290A: Deaths for selected causes by 10-year age groups, race, and 
sex: Death registration states, 1900–32, and United States, 1933–98. 
NCHS/NVSS 15 A.D. January 18; Available at: URL: http://www.cdc.
gov/nchs/nvss/mortality/hist290a.htm.
3. Institute of Medicine. Promoting Cardiovascular Health in the Developing 
World: A Critical Challenge to Achieve Global Health. Washington, DC: 
National Academies Press, 2010.
4. Institute of Medicine. Preventing the Global Epidemic of Cardiovascular 
Disease: Meeting the Challenges in Developing Countries. Washington, 
DC: National Academies Press, 2010.
5. World Health Organization. Prevention and control of non-commu-
nicable diseases – Report of the Secretary-General. World Health 
Organization 2011; 1–18. Available at: URL: http://www.un.org/ga/
search/view_doc.asp?symbol=A/66/83&Lang=E.
6. World Health Organization, World Economic Forum. From burden 
to ‘best buys’: reducing the economic impact of non-communicable 
diseases in low- and middle-income countries. WHO 2011; Available at: 
URL: http://www.who.int/nmh/publications/best_buys_summary.pdf.
7. World Health Organization African Regional Office. Cardiovascular 
diseases in the African region: current situation and perspectives. http://
www.afro.who.int/rc55/documents/afr_rc55_12_cardiovascular.pdf 2004.
8. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality 
from 235 causes of death for 20 age groups in 1990 and 2010: a system-
atic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 
380(9859): 2095–2128.
9. Roth GA, Murray CJ. The Global Burden of Disease Study 2010 does 
not show a rise in the age-standardized mortality rate for cardiovas-
cular disease in sub-Saharan Africa. Prog Cardiovasc Dis 2013; 56(3): 
278–280.
10. Oti SO, van de Vijver S, Kyobutungi C. Trends in non-communicable 
disease mortality among adult residents in Nairobi’s slums, 2003–2011: 
applying InterVA-4 to verbal autopsy data. Glob Health Action 2014; 7: 
25533. doi: 10.3402/gha.v7.25533. eCollection@2014.:25533.
11. Sankoh O, Byass P. Cause-specific mortality at INDEPTH Health and 
Demographic Surveillance System Sites in Africa and Asia: concluding 
synthesis. Glob Health Action 2014; 7: 25590. doi: 10.3402/gha.v7.25590. 
eCollection@2014.:25590.
12. Moran AE, Forouzanfar MH, Roth GA, et al. The global burden of 
ischemic heart disease in 1990 and 2010: the global burden of disease 
2010 study. Circulation 2014; 129(14): 1493–1501.
13. Krishnamurthi RV, Feigin VL, Forouzanfar MH, et al. Global and 
regional burden of first-ever ischaemic and haemorrhagic stroke during 
1990-2010: findings from the Global Burden of Disease Study 2010. 
Lancet Glob Health 2013; 1(5): e259–e281.
14. Moran A, Forouzanfar M, Sampson U, Chugh S, Feigin V, Mensah G. 
The epidemiology of cardiovascular diseases in sub-Saharan Africa: 
the global burden of diseases, injuries and risk factors 2010 study. Prog 
Cardiovasc Dis 2013; 56(3): 234–239.
15. Foreman KJ, Lozano R, Lopez AD, Murray CJ. Modeling causes of 
death: an integrated approach using CODEm. Popul Health Metr 2012; 
10: 1.:1.
16. Roth GA, Forouzanfar MH, Moran AE, et al. Demographic and epide-
miologic drivers of global cardiovascular mortality. N Eng J Med 2015; 
372: 1333–1341. DOI: 10.1056/NEJMoa1406656.
17. Stewart S, Sliwa K. Preventing CVD in resource-poor areas: perspec-
tives from the ‘real-world’. Nat Rev Cardiol 2009; 6(7): 489–492.
